Trends in use and costs of prescription medication in patients with type 1 diabetes: 9-year follow-up after kidney transplantation
暂无分享,去创建一个
Raija Lithovius | Valma Harjutsalo | Carol Forsblom | Markku Saraheimo | Petri K. Koskinen | Per-Henrik Groop | C. Forsblom | P. Groop | V. Harjutsalo | M. Saraheimo | P. Koskinen | R. Lithovius
[1] P Fauchald,et al. PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION , 1995 .
[2] M. Sayegh,et al. Immunosuppressive strategies in transplantation , 1999, The Lancet.
[3] R. Wolfe,et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. , 1999, The New England journal of medicine.
[4] Joshua Miller,et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. , 2002, Transplantation.
[5] Harri Sintonen,et al. Cost analysis of renal replacement therapies in Finland. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] K. Salmela,et al. Two decades of experience with cyclosporine in renal transplantation in Helsinki. , 2004, Transplantation proceedings.
[7] C. Alexander,et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. , 2004, Diabetes care.
[8] Miguel Angel Gentil,et al. Impact of the new drugs in the cost of maintenance immunosuppression of renal transplantation. Is it justified? , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] H. Isoniemi,et al. [Selection of organ transplant drugs is increasing]. , 2004, Duodecim; laaketieteellinen aikakauskirja.
[10] J Raftery,et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. , 2005, Health technology assessment.
[11] Merlin C. Thomas,et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). , 2005, Diabetes care.
[12] Ron Shapiro,et al. Immunosuppression: evolution in practice and trends, 1993–2003 , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] W. John Boscardin,et al. SAS® for mixed models (2nd edn). Ramon C. Littell, George A. Milliken, Walter W. Stroup, Russell D. Wolfinger and Oliver Schabenberger, SAS Institute, Cary, NC, 2006. No. of pages: xii + 814. Price: $89.95. ISBN 10: 1-59047-500-3; ISBN 13: 978-1-59047-500-3 , 2007 .
[14] H. Meier‐Kriesche,et al. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[15] D. Game,et al. Modern renal transplantation: present challenges and future prospects , 2009, Postgraduate Medical Journal.
[16] J. Grinyó,et al. Mycophenolate Mofetil and Calcineurin‐Inhibitor Reduction: Recent Progress , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] W. Arns,et al. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach , 2010, The European Journal of Health Economics.
[18] G. Levy,et al. Progress in Transplantation , 2010, Therapeutic drug monitoring.
[19] F. Luan,et al. Transplantation in Diabetic Kidney Failure Patients: Modalities, Outcomes, and Clinical Management , 2010, Seminars in dialysis.
[20] C. Forsblom,et al. Cumulative cost of prescription medication in outpatients with type 1 diabetes in Finland , 2011, Diabetologia.
[21] Ethan M Balk,et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.
[22] Klemens Budde,et al. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk , 2010, Transplant international : official journal of the European Society for Organ Transplantation.
[23] A. Jardine,et al. Prevention of cardiovascular disease in adult recipients of kidney transplants , 2011, The Lancet.
[24] L. Awdishu,et al. Steroids in kidney transplant patients , 2011, Seminars in Immunopathology.
[25] Teun van Gelder,et al. Current immunosuppressive treatment after kidney transplantation , 2011, Expert opinion on pharmacotherapy.
[26] P. C.-M. Mao,et al. Trends in the use of immunosuppressive agents by outpatients after renal transplantation at a medical center in southern Taiwan. , 2012, Transplantation proceedings.
[27] S. Chadban,et al. Mycophenolate Versus Azathioprine for Kidney Transplantation: A 15-Year Follow-Up of a Randomized Trial , 2012, Transplantation.
[28] Cynthia F Corbett,et al. Risks of subsequent hospitalization and death in patients with kidney disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[29] D. Pavlović,et al. Diabetic nephropathy: diagnosis, prevention and treatment , 2013 .